Clinical development of anticancer agents. A National Cancer Institute perspective = Développement de l'utilisation clinique de substances anticancéreuses. Une perspective du National Cancer InstituteMARSONI, S; WITTES, R.Cancer treatment reports. 1984, Vol 68, Num 1, pp 77-85, issn 0361-5960Article

CLINICAL TRIALSOF NEW DRUGS.DOLLERY CT; WADE OL; TURNER P et al.1977; J. R. COLL. PHYSICIANS LONDON; G.B.; DA. 1977; VOL. 11; NO 3; PP. 226-233; BIBL. 1 REF.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Les ellipticines et aza-ellipticines = Ellipticins and aza-ellipticinsGISSELBRECHT, C; MARTY, M; MIGNOT, L et al.Actualités hématologiques. 1984, Vol 18, pp 193-207, issn 0567-8757Article

Designing phase III or IV trials for vaccines : Choosing between individual or cluster randomised trial designsVAUCHER, Paul.Vaccine. 2009, Vol 27, Num 13, pp 1928-1931, issn 0264-410X, 4 p.Article

Characterization and multiparameter analysis of visual adverse events in Irofulven single-agent Phase I and II trialsRAYMOND, Eric; KAHATT, Carmen; CULLEN, Michael et al.Clinical cancer research. 2004, Vol 10, Num 22, pp 7566-7574, issn 1078-0432, 9 p.Article

La loi Huriet-Serusclat : ce qui a changéDEYGAS, Béatrice.MT. Médecine thérapeutique. 2005, Vol 11, Num 1, pp 11-13, issn 1264-6520, 3 p.Article

Guidelines for clinical evaluation of antiepileptic drugsEpilepsia (Copenhagen). 1989, Vol 30, Num 4, pp 400-408, issn 0013-9580Article

Méthodologie des essais cliniques en cancérologie : médicaments anticancéreux (2e partie) = Design of clinical trials in oncologyTRANCHAND, Brigitte; CHABAUD, Sylvie; COLOMBAN, Olivier et al.La Lettre du pharmacologue (Boulogne). 2008, Vol 22, Num 3, pp 98-110, issn 0984-452X, 13 p.Article

Journées de pharmacogie cliniqueThérapie (Paris). 1992, Vol 47, Num 5, pp 455-465, issn 0040-5957Conference Proceedings

Les essais cliniques = Clinical trialsZIVIN, J.Pour la science. 2000, Num 272, pp 100-105, issn 0153-4092Article

Klinische Erfahrungen mit dem kurzwirksamen Opioid Alfentanil (Rapifen^®) = Essais cliniques de l'opioide à action courte alfentanil (rapifen*) = Clinical experiences with the short acting opioid alfentanil (rapifen*)JOST, U; HIRSCHAUER, M; SCHMID, A et al.Anästhesie, Intensivtherapie, Notfallmedizin. 1984, Vol 19, Num 1, pp 8-13, issn 0174-1837Article

Anticorps monoclonaux à usage thérapeutique: spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long termePAINTAUD, Gilles; DIVINE, Marine; LECHAT, Philippe et al.Thérapie (Paris). 2012, Vol 67, Num 4, pp 319-327, issn 0040-5957, 9 p.Article

L'analyse en intention de traiter et analyse per protocoleCHABAUD, Sylvie; CUCHERAT, Michel.MT. Médecine thérapeutique. 2004, Vol 10, Num 5, pp 350-355, issn 1264-6520, 6 p.Article

Design issues of randomized phase II trials and a proposal for phase II screening trialsRUBINSTEIN, Lawrence V; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 7199-7206, issn 0732-183X, 8 p.Article

Dispensation ambulatoire du médicament pour essai clinique : Place du conseil pharmaceutique = Clinical trials and outpatient dispensation: the pharmaceutical counselling placeBOSSAERT, Sandra; CORVAISIER, Stéphane; LIVROZET, Agnès et al.Journal de pharmacie de Belgique. 2003, Vol 58, Num 2, pp 44-50, issn 0047-2166, 7 p.Article

Time to mandate data release and independent audits for all clinical trialsHAINES, Ian E; GABOR MIKLOS, George L.Medical journal of Australia. 2011, Vol 195, Num 10, pp 575-577, issn 0025-729X, 3 p.Article

Randomized Phase II Trials: Inevitable or Inadvisable?GAN, Hui K; GROTHEY, Axel; POND, Gregory R et al.Journal of clinical oncology. 2010, Vol 28, Num 15, pp 2641-2647, issn 0732-183X, 7 p.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

Methodology of superiority vs. equivalence trials and non-inferiority trialsCHRISTENSEN, Erik.Journal of hepatology. 2007, Vol 46, Num 5, pp 947-954, issn 0168-8278, 8 p.Article

Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC#4366650 and cryopreserved autologous marrow transplantation for retractory cancer: a phase I-II study = BCNU à haute dose et greffe autologue de moelle cryocongelée dans les tumeurs résistantes. Une étude phase I-IIPHILLIPS, G. L; FAY, J. W; HERZIG, G. P et al.Cancer. 1983, Vol 52, Num 10, pp 1792-1802, issn 0008-543XArticle

Early clinical trials of mitoxantrone = Premiers essais cliniques de la mitoxantroneBODEY, G. P; VALDIVIESO, M; HWEE-YONG YAP et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 103-114, issn 0146-0447Article

MANAGEMENT OF TRIALS IN THE DEVELOPMENT OF CANCER CHEMOTHERAPY.WILLIAMS CJ; CARTER SK.1978; BRIT. J. CANCER; GBR; DA. 1978; VOL. 37; NO 3; PP. 434-447; BIBL. 24 REF.Article

THE CANCER THERAPY EVALUATION PROGRAM OF THE NATIONAL CANCER INSTITUTEMUGGIA FM; CARTER SK; MACDONALD JS et al.1981; SEMIN. ONCOL.; ISSN 0093-7754; USA; DA. 1981; VOL. 8; NO 4; PP. 394-402; BIBL. 49 REF.Article

CLINICAL TRIALS IN CANCER CHEMOTHERAPY.CARTER SK.1977; CANCER; U.S.A.; DA. 1977; VOL. 40; NO 1, SUPPL.; PP. 544-557; BIBL. 1 P. 1/2Article